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Abstract
Although it is generally believed that the beneficial effect of loop diuretics is the result of a rapid increase in diuresis, substantial 
evidence, from a large number of in vitro and in vivo experiments, has accumulated showing that administration of furosemide causes 
direct vascular effects, which probably contribute to its acute clinical effects, Several mechanisms are involved in the vascular response to 
loop diuretics. The role of the renin-angiotensin-aldosterone axis, prostaglandins and the direct vascular effects of loop diuretics on both 
the arterial and venous parts of the vasculature are discussed.
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1. Introduction
Diuretic therapy has proved to be effective in the 
treatment of acute and chronic heart failure. The potent 
loop diuretics, furosemide and bumetanide, are frequently 
used in the treatment of disease states characterized by 
fluid and sodium retention. After intravenous administra­
tion of furosemide, clinical relief of symptoms often pre­
cedes the increase in diuresis in patients with acute heart 
failure, suggesting the presence of an extrarenal effect. 
Although it is generally believed that the beneficial effect 
of loop diuretics is the result of a rapid increase in diuresis, 
substantial evidence, from a large number of in vivo and in 
vitro experiments, has accumulated showing that adminis­
tration of furosemide causes vascular effects, which proba­
bly contribute to its acute clinical effects.
At first sight the reports on the vascular non-diuretic 
effects of furosemide seem conflicting. However, a great 
deal of the disparity in the results seems to be due to 
differences in the vascular bed studied (arterial or venous, 
renal or pulmonary, etc.), the species studied, the timing 
(acute vs. chronic effects), systemic vs. local effects, direct 
vs, indirect effects and differences in disease states. In this 
paper the literature on vascular effects of loop diuretics
t
(with emphasis on furosemide) is reviewed with reference 
to the differences in experimental protocols. Finally, some 
general conclusions are drawn, and suggestions for future 
investigations are given.
2« In vitro studies
The direct vascular effects of furosemide are difficult to 
study in vivo because of interfering counteracting mecha­
nisms which may even completely mask direct effects. In a 
number of in vitro studies the presence of Na+K+Cl~ 
co-transport activity has been demonstrated in endothelial 
as well as vascular smooth muscle cells [1-3], and this 
observation represents a primary focus of interest with 
regard to the vascular effects of furosemide. However, 
inhibition of Na+K+Cl_ co-transport activity occurs only 
at high furosemide concentrations. These concentrations 
are reached in the renal tubule, but not in the cardio­
vascular system [4]. It should be emphasized that in all in 
vitro studies much higher concentrations were needed to 
induce vascular responses than in the human in vivo 
situation. An additional difference causing much higher 
concentrations of free furosemide is the absence of protein 
binding in the media used.
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Table 1
In vitro experiments on the vascular effects of furosemide
Vasculature Species Drug concentration Main effects Reference
Arterial
Aorta Rabbit 330 jjLg/ml Hyperpolarisation and relaxation of smooth muscle cells [6]
Mes Rat 1—81 ¡jug/ml Dose-dependent inhibition of response to norepinephrine [7]
Ear and renal Rabbit 20 jJLg/ml Inhibition of response to norepinephrine, attenuated by albumin [8]
Ear Rabbit 20—330 |xg/ml Direct endothelium-independent relaxing effect £9]
Pul, mes, tib Dog 32—960 [xg/ml No relaxation of precontracted arteries [101
Tail Rat 5 m g/kg * Endothelium-dependent reduction of electrically stimulated contraction [11]
Venous
Portal Rat 1-100 p>g/ml Reduction of response to norepinephrine and angiotensin II [5]
Portal Rabbit 20 jxg/mJ Inhibition of response to norepinephrine, attenuated by albumin [8]
Pulmonary Dog 32-960 |xg/ml Endothelium-independent relaxation of norepinephrin-induced contraction [10]
Ear =  central ear artery; Mes =  mesenteric; Pul — pulmonary; Tib =  anterior tibia] arteiy. 
Administered dose instead of furosemide concentration.
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The in vitro studies focussing on the vascular effects of 
furosemide are summarized in Table 1. In the early 1970’s 
an inhibitory effect of furosemide on the vasoconstrictor 
response to norepinephrine and angiotensin II was ob­
served in the rat portal vein [5]. It was demonstrated that 
incubation with furosemide causes a membrane hyperpo­
larisation of 5.5 mV in the relaxed rabbit pulmonary artery 
[6]. Many vasodilatory agents act by hyperpolarisation of 
the plasma membrane and subsequent closure of voltage- 
dependent calcium channels, so this observation is consis­
tent with, and possibly explains, the direct vasodilatory 
action of furosemide.
Furosemide appeared to have a direct vascular effect in 
the perfused mesenteric vascular bed of the rat [7]. In an in 
vitro study with arterial vascular smooth muscle in seg­
ments of rabbit blood vessels, furosemide (20 juig/ml) 
induced a small decrease in resting tension [8],
In the isolated rabbit central ear artery a direct relaxing 
effect of furosemide on isolated vessel segments was 
concentration-dependent (0.1 -1.0 mM furosemide) [9]. It 
was demonstrated that inhibition of Na+K+Cl~ co-trans­
port activity or hyperpolarization of the membrane was 
unlikely to be the sole mechanism responsible for the 
vasorelaxant effect of furosemide.
In an in vitro study using dogs it was demonstrated that 
furosemide did not have a direct effect on arterial smooth 
muscle, but exhibits selective venorelaxant activity [10]. 
The magnitude of this effect was most pronounced in the 
pulmonary vascular bed. Moreover, the vasorelaxant activ­
ity of furosemide was independent of endothelium, nitric 
oxide, cyclic GMP and prostanoids.
The role of the endothelium in the direct vascular 
effects of furosemide is still unclear. Whereas one report 
on an ex vivo experiment showed that the effect of 
furosemide on the response to sympathetic stimulation was 
endothelium-dependent [11], others did not find an impor­
tant role for the endothelium in mediating the relaxation 
caused by furosemide in vitro [9], The discrepancy be­
tween these results with respect to the endothelium-de- 
pendency may be caused by the different concentrations of 
furosemide studied and by the use of albumin-containing 
solutions [8].
3. In vivo studies after systemic administration
During the 1970’s interest increased in the vascular 
effects of diuretics. With the development of tools to 
monitor changes in haemodynamic parameters, these ef­
fects could be described more appropriately. In most of 
these studies, as discussed in the next paragraph and 
summarized in Table 2, loop diuretics were administered 
systemically. However, it should be noted that the changes 
in haemodynamic parameters observed directly after ad­
ministration of the loop diuretic do not necessarily imply 
direct vasoactivity of the loop diuretic.
A study by Dikshit et al. is one of the first reports that 
focussed on the vascular effects of loop diuretics [12]. In 
20 patients with left ventricular failure, intravenous admin­
istration of furosemide caused a prompt fall in left ventric­
ular filling pressure, which was accompanied by an in­
crease in venous compliance, the latter being a marker for 
venodilatation. These phenomena preceded an increase in 
urine and electrolyte output. In dogs, furosemide produced 
a rapid reduction in pulmonary wedge pressure and an 
increase in venous compliance even though the ureters 
were ligated [13]. These observations indicate that this 
venous effect may not have been the result of a decrease in 
plasma volume. The dissociation of diuretic and vascular 
effects was confirmed in a study with hypertensive pa­
tients: despite a fall in blood pressure, plasma volume did 
not change after administration of furosemide in combina­
tion with a high salt intake [14]. In patients with peripheral 
edema and mild hypertension the use of furosemide re­
sulted in a decrease in mean arterial pressure, cardiac 
output and total peripheral resistance, whereas the venous 
capacitance increased without change in plasma and blood 
volume [15]. However, the dissociation between venodila- 
tion and plasma volume is not always obvious. In patients 
with mild heart disease or hypertension, 80 mg i.v. 
furosemide caused a decrease in right atrial pressure, pul­
monary arterial pressure and pulmonary artery wedge pres­
sure (signifying increased venous compliance), together 
with a decrease in cardiac index within 20 min [16]. In this 
study, a haemoconcentration was observed as well, sug­
gesting that the haemodynamic effects were secondary to 
intravenous volume reduction through diuresis.
The relationship between haemodynamic and hormonal 
changes after furosemide injection and during chronic 
furosemide treatment was studied in patients with conges­
tive heart failure [17]. Cardiac output decreased signifi­
cantly after furosemide injection (1 mg/kg body weight), 
reached its nadir after 90 min and returned to baseline 
within 4 h. The mean pulmonary arterial pressure de­
creased steadily throughout the 4 h observation period. 
These changes were not accompanied or preceded by 
changes in plasma renin activity, angiotensin II or aldos­
terone. In this study patients were on a fixed diet; urine 
losses were not replaced isovolumetrically. After continu­
ous oral furosemide therapy during 8-10 days reciprocal 
changes between haemodynamic and hormone indices were 
observed. As the diuretic response diminished, cardiac 
output and pulmonary arterial pressure declined, whereas 
the renin-angiotensin system was activated. This suggests 
that during chronic therapy plasma renin activity and 
angiotensin II might counteract the vasodilatory effects of 
furosemide. However, there are some reports that are in 
disagreement with this hypothesis [18,19]. In patients with 
severe congestive heart failure, intravenously administered 
furosemide caused an early fall in stroke volume index and 
a quick transient increase in the systemic vascular resis­
tance, a rise in mean arterial blood pressure (within 20 min
Table 2
In vivo experiments on the acute haemodynamic effects of furosemide
Species (disease state) Dose Main effects Reference
Human (AHF) 0.5-1.0 m g/kg i.v. Decrease PWP, increase VC, MAP and CO unchanged [12]
Dog (ligated ureters) 2 m g/kg Decrease PWP, PAP, increase VC, SVR, MAP unchanged [13]
Human (hypertension) 120-4000 mg/day p.o. Decrease MAP, blood volume unchanged [14]
Human (hypertension) 120-200 mg/day p.o. Decrease MAP and SVR, increase VC, blood volume unchanged [15]
Human (hypertension) 80 mg i.v. Decrease PAP and PWP and blood volume, VC forearm unchanged [16]
Human (CHF) 1 m g/kg Decrease PAP and CO [17]
Human (CHF) 1.3 ±0.6 m g/kg i.v. Decrease SVI, increase MAP and SVR [18]
Rat (hypertension) 3 m g/kg i.v. Decrease CO and SVI, increase SVR [19]
Human (salt depleted) 5-80 mg i.v. Increase VC [20]
AHF =  acute heart failure; CHF =  chronic heart failure; CO = cardiac output; i.v. =  intravenously; MAP =  mean arterial pressure; PAP = pulmonary arterial pressure; p.o. = orally; PWP =  pulmonary wedge 
pressure; SVI =  stroke volume index; SVR =  systemic vascular resistance; SVI =  stroke volume index; VC = venous capacitance.
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Table 3
Experiments on the role of the kidney in the vascular effects of furosemide
Species (disease state) Dose Main effects Reference
Human (functionally anephric) 3 m g/kg i.v. Increase FBF, unchanged SBP, VC, weight, hematocrit, PRA [21]
Human (anephric) 80 mg i.v. VC and BP unchanged [22]
Rat (acute nephrectomy) 5 m g/kg i.v. Complete inhibition of vasoconstrictor response to NE and AT II [23]
Dog (ligation ureters) 2 m g/kg i.v. Decrease PAP and PWP, increase SVR and VC, BP unchanged [13]
Dog (acute nephrectomy) 2 m g/kg i.v. No haemodynamic changes [13]
AT II =  angiotensin II; BP =  blood pressure; FBF = forearm blood flow; i.v. =  intravenously; NE =  norepinephrin; PAP =  pulmonary arterial pressure; PRA =  plasma renin activity; PWP =  pulmonary 
wedge pressure; SBP =  systolic blood pressure; SVR =  systemic vascular resistance; VC =  venous capacitance.
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after injection), associated with an increase in plasma renin 
activity, norepinephrine and plasma arginine-vasopressin 
levels [18]. These results were strengthened by the out­
come of a study in spontaneously hypertensive rats [19] in 
which furosemide (3 mg/kg) caused an early fall in stroke 
volume and cardiac index. A decrease in mean arterial 
blood pressure was observed after a delay of 2 to 4 h, 
which was sustained for 6 to 8 h after injection. Total 
peripheral vascular resistance increased substantially and 
returned to baseline range within 24 h. The supposed 
mechanisms involved in the differences between the acute 
and chronic effects include an adaptation of baroreflex 
activity, a direct vasodilatory effect of diuretics, a de­
creased reactivity of the vascular system to pressor stimuli, 
a reduction of extracellular body fluid volume, and/or the 
production of endogenous vasodilator substances mediated 
by furosemide.
The dose-dependency of the vascular effects of 
furosemide was characterized in healthy volunteers by 
using dosages ranging from 5 to 80 mg [20]. Increases in 
venous capacitance were observed 5 min after i.v. adminis­
tration of 5 and 10 mg furosemide. Over the dose range 
20-80 mg, no significant increases were observed. How­
ever, after 10 min venous responses showed significant 
increases in venous capacitance, equally for all dosages 
used. An oral dosage of 80 mg furosemide produced a rise 
in venous capacitance 15 min after administration and a 
decrease in forearm bloodflow 15-60 min after administra­
tion. A decrease in calf blood flow was observed within 15 
min following administration of furosemide, regardless of 
salt balance or use of indomethacin [20]. This latter effect 
of furosemide was associated with a rise in plasma renin 
activity and was not observed in anephric patients [21].
4. The role of the kidneys
In an attempt to elucidate the role of the kidneys in the 
haemodynamic effect of furosemide, vascular responses 
were studied in functionally anephric hypertensive patients 
[21]. In contrast to experiments in subjects with normal 
renal function, intravenously administered furosemide 
caused a significant increase in forearm blood flow of 55% 
within 15 min, whereas venous capacitance, weight hemat­
ocrit and plasma renin activity were unchanged (see Table 
3). Possibly, this represents a direct vascular effect of 
furosemide, which becomes unmasked in the absence of 
counteracting mechanisms, such as the renin-angiotensin 
system, In another study, the effect of intravenously ad­
ministered furosemide on venous capacitance and calf 
blood flow was compared in healthy volunteers and 
anephric patients [22]. Venous capacitance increased in 
healthy volunteers, but not in anephric patients. Moreover, 
this effect of furosemide required a salt-retaining state and 
it could be blocked by the use of the cyclo-oxygenase 
blocker, indomethacin, suggesting an important role for
renal prostaglandins in the systemic vascular effects of 
furosemide.
Furosemide (5 m g/kg) attenuated the vasoconstrictor 
responses of the mesenteric blood vessels in the rat to both 
exogenous angiotensin II and norepinephrine [23]. Acute 
bilateral nephrectomy or treatment with indomethacin (2 
mg/kg i.v.) completely prevented this inhibitory effect. In 
a subsequent report the inhibitory effect of furosemide on 
the vasoconstrictor response to sympathetic nerve stimula­
tion was absent after chemical renal medullectomy [24]. 
The authors explained this effect by postulating that in the 
renal medulla non-prostanoid vasodilatory lipids are pro­
duced which mediate the vasodilatory effect of furosemide 
[25]. Intrarenal prostaglandins probably are involved in the 
release of such a lipid. Although substantial evidence of a 
direct vascular effect of furosemide is available from 
several in vitro experiments (see foregoing and Table 1), a 
coincidence of hormonal changes with the observed vascu­
lar effects was not considered.
5. The renin-angiotensin-aldosterone system
The release of renin is controlled by three mechanisms: 
the intrarenal baroreceptor, the sympathetic nervous sys­
tem and the macula densa receptor [26]. Results of some 
studies show a participation of prostaglandins in renin 
release [27-29]. It was demonstrated that prostaglandins 
mediate renin release in response to intrarenal baroreceptor 
stimulation [30]. On the other hand, renin release due to 
symthathetic nerve stimulation is prostaglandin- 
independent [31]. Micropuncture experiments in rats indi­
cate that renin release resulting from macula densa recep­
tor stimulation during sodium deprivation is prosta­
glandin-dependent [29], whereas in dogs the macula densa 
mechanism of renin release could be blocked by inhibition 
of prostaglandin synthesis [32]. It is known from ex vivo 
experiments that furosemide exerts a direct stimulating 
effect on renin secretion [33], In the isolated perfused rat 
kidney, furosemide-stimulated renin secretion did not re­
quire intact PGI2 synthesis [34]. The authors proposed that 
increased prostaglandin production and increase of renin 
release after furosemide administration is not causally 
related, but may be based on a common response to 
changes in sodium balance. In fact, prostaglandin synthesis 
could even be a counteracting mechanism participating in 
the vasoconstrictor action of angiotensin II [35].
The importance of angiotensin II in the vascular effects 
of 5 mg intravenously administered furosemide was stud­
ied in healthy volunteers [36]. Captopril 50 mg abolished 
the acute increases in venous capacitance and attenuated 
the increase in forearm vascular resistance. The mecha­
nism suggested is that angiotensin II is formed secondarily 
to furosemide-stimulated renin release, and that the de­
crease in forearm blood flow is the result of the vasocon­
strictive effect of angiotensin II. Angiotensin II receptors
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are virtually absent in veins, so the net effect appears to be 
venodilation due to the angiotensin-induced release of 
vasodilatory prostaglandins from the kidney [36]. This 
view may not be entirely correct, as it has been demon­
strated that angiotensin II has a direct venoconstrictive 
effect on the human dorsal hand vein [37].
To determine whether the vascular effects of furosemide 
are shared by bumetanide, another frequently used loop 
diuretic, the vascular and renal effects of equipotent 
dosages of furosemide and bumetanide were compared in 
healthy volunteers with moderate [38] and severe salt 
depletion [39]. In the case of moderate salt depletion, both 
furosemide (10 and 100 mg) and bumetanide (250 jmg and 
250 mg) caused an increase in renal blood flow in both 
dosages. Changes in peripheral vascular responses did not 
differ from placebo. Both treatments led to an acute in­
crease in urinary prostaglandin metabolite excretion (which 
may be a reflection of an increased renal blood flow) and 
plasma renin activity (the latter not increased by 
bumetanide 250 jxg). Angiotensin II was increased signifi­
cantly 30 min after 100 mg furosemide and 2.5 mg 
bumetanide. Plasma norepinephrine was not influenced by 
any of the treatments [38]. In contrast with these observa­
tions was the vascular response to furosemide (10 and 20 
mg) and bumetanide (250 and 500 jjtg) in marked salt 
depletion [39]. Significant reductions in forearm blood 
flow were observed after both furosemide dosages, but not 
after either of the bumetanide dosages. Both drugs had no 
significant influence on venous capacitance. Furosemide 
induced an increase in plasma renin activity, whereas 
bumetanide did not. The differences between furosemide 
and bumetanide with regard to acute arterial vasoconstric­
tive activity may be attributed to the ability of furosemide 
(and the disability of bumetanide) to stimulate acute renin 
release from the kidney.
The discrepancy between the results of this study [39] 
and that by Johnston et al. [38] with respect to vascular 
effects may be caused by differences in the degree of salt 
depletion. This is emphasized by others [17,40]. There are 
no in vitro studies that compare the vascular effects of 
furosemide and bumetanide.
As illustrated in the foregoing paragraphs, the total 
body sodium content is an important factor in the modula­
tion of the indirect vascular response to furosemide. Ad­
ministration of a loop diuretic to a salt-depleted subject 
may further activate the renin-angiotensin system, causing 
a more pronounced arterial vasoconstriction.
6. Prostaglandins
In 1975 it was shown in dogs that pretreatment with the 
cyclo-oxygenase inhibitor indomethacin blocked the in­
crease in renal blood flow caused by furosemide [41]. 
Since then several studies have explored the role of prosta­
glandins in the natriuretic and vascular responses to
furosemide [30,34,40,42-52]. It is of importance to distin­
guish the effects of circulating prostaglandins of renal 
origin from prostaglandins produced in the local (ex- 
trarenal) vascular bed, since the furosemide-induced vascu­
lar effects may well be dependent on prostaglandins lo­
cally produced in the vessel wall. However, in in-vivo 
experiments it is difficult to study these two sources of 
prostaglandins separately.
The kidney releases PGI2, PGE2, PGF2a and throm­
boxane A2 [42]. PGI2 and PGE2 possess important va­
sodilatory properties under conditions of prior vasocon­
striction. Prostaglandin-induced vasodilatation plays an im­
portant role in the maintenance of glomerular filtration and 
perfusion by dilatation of the afferent arteriole in a salt-de­
pleted state, when the renin-angiotensin system is acti­
vated [53].
Furosemide has been shown to increase the urinary 
excretion of prostaglandin [38,50,52]. Whether this is 
caused by increased renal blood flow or by increased 
production of prostaglandins is unclear. On the other hand, 
reports on the effects of inhibition of prostaglandin synthe­
sis on furosemide-induced natriuresis are conflicting, prob­
ably due to variations in salt balance during the experi­
ments [42].
In healthy volunteers PGI2 induced renin release and 
furosemide-induced renin release were associated with re­
nal PGI2 formation [54]. In a study performed in nor- 
motensive volunteers, indomethacin (75 mg) decreased 
both the peak urine flow rate and total sodium excretion 
within 1 h of a 30 mg i.v. furosemide dose, while an 
increase in renal plasma flow and glomerular filtration rate 
after furosemide was inhibited [48], The increase in urinary 
excretion of PGE2 was abolished by indomethacin. The 
urinary excretion of a metabolite of systemic PGI2 was 
unaltered after furosemide injection. The authors stated 
that the early haemodynamic effects of furosemide depend 
on an increased synthesis of prostaglandins, particularly 
PGE2 and probably also PGI2. However, it is questionable 
whether the non-renal effects are a result of increased 
circulating prostaglandin levels [24,43]. Arguments that 
underscore these doubts are: prostaglandins are very labile, 
are rapidly metabolized, and increased plasma levels of 
prostaglandins have never been measured after furosemide 
administration.
Although the studies mentioned above suggest that 
furosemide induces an increment in renal prostaglandin 
production, they do not clarify whether systemic prosta­
glandin synthesis— the local production in the extrarenal 
vasculature—is increased by furosemide. Mediation of the 
cardiovascular effects of furosemide by vascular products 
of arachidonate metabolism were studied in ex vivo experi­
ments using an isolated perfused canine lung lobe [47]. 
Furosemide decreased the mean pulmonary artery pressure. 
This direct arterial vasodilatory activity of furosemide was 
similar to that of PGI2 and could be inhibited with indo­
methacin, suggesting that furosemide induces a local pro-
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Fig. 1. Diagrammatic scheme illustrating the possible mechanisms of furosemide-induced vasoactivity on artery and vein. The upper part of the figure 
represents direct vascular effects, whereas the lower part represents the vascular effects mediated by hormonal changes.
duction of PGI2 in resistance and/or capacitance vessels. 
Recently, an in vitro study was published showing that 
furosemide in primary cultured bovine aortic endothelial 
cells stimulated the formation of endothelium-derived 
kinin, a potent stimulator of endothelial nitric oxide and 
PGI2 formation [43]. These experiments suggest that 
haemodynamic effects of furosemide are mediated by 
prostaglandins released from the local vasculature.
7. Conclusions
Although in the past 25 years much research has been 
done, the exact mechanism by which furosemide induces 
its vascular effects remains unclear. In Fig. 1 the mecha­
nisms involved in the vascular effects are shown. It seems 
clear that both direct and indirect mechanisms play a role. 
The venous vascular response to furosemide appears to be 
a direct effect, while the arterial response in vitro only 
occurs at supratherapeutic concentrations, and probably is 
mediated and modified by other factors like the degree of 
salt depletion, renin, angiotensin II and prostaglandins in 
vivo. The prostaglandins are either produced by the kid­
neys or by the endothelium, whereas the precise role of the 
endothelium has not yet been completely clarified.
Much attention has been paid to the arterial response, 
while the effects on the venous component have only been 
roughly monitored due to a lack of sensitive techniques to 
monitor local venous effects. However, especially in pa­
tients suffering from cardiac failure, the venous vasodila­
tion might be of importance in the observed acute benefi­
cial effects.
There are two methods available to study direct vascu­
lar effects in vivo. First, direct effects on resistance arteries 
in the human forearm can be studied with the perfused 
forearm technique. Using this method, direct vasoconstric­
tive or vasodilator effects on resistance arteries in the 
human forearm can be examined by drug administration 
into the brachial artery and venous occlusion plethysmo- 
graphic recordings [55]. Second, with a linear variable 
differential transducer it is possible to measure direct 
venous vascular effects on a selected dorsal hand vein 
[56,57], With these methods it is possible to examine local 
vascular effects without provoking systemic counterregula- 
tory effects. In a quest to explore the genuine direct 
vascular effects of loop diuretics in vivo, these methods 
provide the best options for future studies.
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